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Background 
Epidemiology 
Pheochromocytoma is a rare endocrine neoplasm which, if untreated, is most 
often fatal, but if diagnosed, can be safely excised in 90% of cases. Up to 10% of 
pheochromocytomas are familial, inherited by itself, as part of a MEN syndrome, or in 
association with a neuroectodermal dysplasia (MANGER et al. 1993). Familial transmission 
is thought to be autosomal dominant, with varying degrees of penetrance (CUSHMAN et al. 
1962). MEN syndromes were first described in 1961, when Sipple characterized a 
syndrome of concomitant pheochromocytoma and medullary carcinoma of the thyroid 
(SIPPLE et al. 1961). This was later renamed as multiple endocrine neoplasia (MEN) type 
IIA, with the addition of parathyroid adenoma. In 100% of patients in families with the 
MEN IIA allele, medullary carcinoma of the thyroid develops; in 33%, 
pheochromocytoma is diagnosed (bilaterally in the majority), and 34% become hyper 
parathyroid (CANCE et al. 1985). Other studies of MEN II families have shown genetic 
abnormalities. Eight of 10 MEN II kindreds were shown to have a point mutation of the 
RET proto-oncogene in chromosome 10, near its centromere, whereas the remaining two 
families were found to have mutations in the von Hippel-Lindau gene, present on 
chromosome 3 (NEUMANN et al. 1995). 
These MEN II-associated pheochromocytomas tend to secrete substantially more 
epinephrine than norepinephrine. Thus, with the current management of screening MEN 
II family members at risk after undergoing mutational analysis, an elevated urinary 
epinephrine level may be the only abnormality suggesting the tumor in an asymptomatic 
patient. The neuroectodermal dysplasia is also associated with pheochromocytoma. Von 
Recklinghausens disease, or neurofibromatosis, has one of the strongest relationships. 
The disease is characterized by multiple neurofibromas of peripheral nerves, presenting 
as subcutaneous or intradermal nodules. Other features include vascular and hairy nevi, 
cutaneous polyps, and café au lait spots. The prevalence of pheochromocytoma in 
patients with von Recklinghausens disease is 1% to 2%. Conversely, 5% of 
pheochromocytoma patients have neurofibromatosis. Other neuroectodermal dysplasia 
linked to pheochromocytoma include Sturge-Weber syndrome, consisting of familial 
hemangiomas, angiomatous brain malformations, seizures, tuberous sclerosis, mental 
deficiency, epileptiform seizures, and multiple adenoma sebaceum (BONZANI et al. 1999). 
Pheochromocytomas can occur at any age, from infancy to old age, being quite 
uncommon after age 60. They account for only 0.1% to 0.2% of all cases of diastolic 
hypertension (MANGER et al. 1997), and they have an incidence of 0.005% to 0.1% in the 
general, unscreened population. Pheochromocytomas occur at a rate of about 1 in 
1,000,000 to 1 in 50,000 persons per year and about 1 in 1,000 hypertensive individuals 
(CRYER et al. 1985). As many as 800 persons may die annually in the United States as a 
result of associated complications (GRAHAM et al. 1951). One review cites a slight female 
predilection (CHONG et al. 1974); others show no difference in incidence (MELMON et al. 
1965). Additionally, another study has shown a slightly more common incidence in the 
right adrenal gland (SAMAAN et al. 1988). Ten to twenty percent of all patients with 
pheochromocytomas are children. These tumors display some different characteristics 
than those of adults. Roughly two-thirds of the pediatric pheochromocytoma populations 
are prepubertal boys; the tumors have a much higher likelihood of being multiple (32%), 
bilateral (24%), and extraadrenal (15%-31%) than in adults (STACKPOLE et al. 1963).  
 Traditionally, 10% of all pheochromocytomas were believed to lie outside the 
adrenal medulla. A recent review by Whalen and colleagues summarized the literature to 
date and reported the incidence to be 18%. Eighty-five percent of extraadrenal 
pheochromocytomas are infradiaphragmatic; 98% of all pheochromocytomas lie below 
the diaphragm, with 1% residing in the cervical region and the remaining 1% being 
located intrathoracically (WHALEN et al. 1992). 
 To better delineate the nature and location of these extraadrenal tumors, the term 
paraganglion system was developed as a replacement for the term pheochromocytoma. It 
is defined as a widely dispersed collection of specialized neural crest cells, arising in 
association with the segmental or collateral autonomic ganglia, which migrate to one of 
three final destinations (BONZANI et al. 1999): 
1. Adjacent to arterial vessels and cranial nerves of the head and neck 
2. Alongside the sympathetic plexus and chains, extending from the neck to the 
pelvis 
3. Adrenal medulla 
Thus, these extraadrenal tumors can occur anywhere along the sympathetic 
nervous system. Certain variants are specifically named. A chemodectoma arises from 
paraganglia of the carotid body. A glomus jugulare tumor has its origins in paraganglia of 
the intracranial branches of the ninth and tenth cranial nerves. Ganglioneuromas arise 
from postganglionic sympathetic neurons. All extraadrenal chromaffin tissues behave 
similarly to those within the adrenal medulla. Even though trends are emerging to support 
use of these anatomic descriptions, the label of pheochromocytoma is still very much 
ingrained into the medical literature, and because of its universal recognition, it is used 
here to apply to all variants of these neural crest tumors (BONZANI et al. 1999). 
 
Symptoms 
 The clinical presentation of pheochromocytoma is attributable to the physiologic 
effects of its circulating catecholamines. The predominant sign is hypertension. Half of 
cases yield sustained hypertension, whereas approximately 45% of patients experience 
paroxysms of high blood pressure. The remaining 5% are normotensive. It is highly 
unusual to correctly diagnose pheochromocytoma in the absence of hypertension, except 
in multiple endocrine neoplasia II (MEN II) family members at known risk, who have 
biochemical screening performed. Hypotension can occur, and some patients may even 
alternate between hypertensive and hypotensive episodes. Another important diagnostic 
clue is the evaluation for pheochromocytoma in postural hypotension. When seen in a 
hypertensive patient not on hypertensive medication, it raises strong clinical suspicion for 
the presence of pheochromocytoma. Probable mechanisms for this include autonomic 
insensitivity, resulting from excessive circulating catecholamines, and hypovolemia. 
Postural hypotension is more common in sustained hypertension (BONZANI et al. 1999). 
 Headache is by far the most common symptom in pheochromocytoma, occurring 
in 92% of paroxysmal patients and 72% of those with stable hypertension (MANGER et al. 
1993). Hyperglycemia is seen commonly. In patients with preexisting diabetes mellitus, 
impaired glucoregulation develops, sometimes presenting with diabetic ketoacidosis. This 
impaired glucose metabolism may be due to beta-adrenergic receptor desensitization as a 
modulator of insulin resistance (DI PAULO et al. 1989). 
 Hypocalcaemia is noted, even in the absence of the MEN syndromes, which 
resolves after surgical resection of the tumor. In most cases, this is apparently related to 
the secretion of parathyroid-related peptide, which does not cross-react with any of the 
parathyroid hormone (PTH) assays currently used. Thus, PTH levels will be suppressed if 
measured. Nausea and vomiting may occur, especially in conjunction with severe 
headache. Weakness and weight loss are present, despite a normal or increased appetite. 
Chest or abdominal pain may mimic coronary artery disease or an acute abdomen. 
Excessive catecholamines decrease intestinal mobility and result in severe constipation, 
whereas the rare VIP-secreting tumor predisposes the patient to diarrhea. These 
paroxysmal spells are elicited by multiple stimuli, including pain, tumor manipulation 
(such as an abdominal examination), exercise, anxiety, bladder distention or voiding (in 
the case of bladder pheochromocytomas), constipation, trauma, sexual intercourse, 
diagnostic procedures, radiographic contrast media, surgery, and anesthesia. 
Additionally, certain foods, for example, tyramine-containing cheeses, beer, and wines, 
as well as medications, such as phenothiazines, tricyclic antidepressants, ACTH, 
histamine, glucagons, beta-blockers, metoclopramide, nicotine, angiotensin II analogues, 
and epinephrine, can all promote an attack (BONZANI et al. 1999). 
 
Diagnosis 
 Biochemical confirmation of pheochromocytoma is crucial before proceeding to 
definitive treatment, and the cornerstone of diagnosis remains the measurement of 24-
hour urinary catecholamine levels. Major substances that are currently used for 
pheochromocytoma detection include plasma catecholamine, urinary free catecholamine, 
urinary metanephrine, and normetanephrine, as well as urinary vanillylmandelic acid 
(VMA) levels. Metanephrine and VMA represent two of the main metabolites of 
norepinephrine and epinephrine (BONZANI et al. 1999). The usefulness of these assays 
arises from the fact that 95% to 99% of patients with pheochromocytoma have elevated 
levels of catecholamines in their blood or urine (SJOERDSMA et al. 1966). 
 A finding of elevated urinary catecholamines does not eliminate other diseases. 
The differential diagnosis of increased urinary catecholamines includes intracranial 
lesions, carcinoid syndrome, acute porphyria, factitious hypertension, clonidine 
withdrawal, and hypoglycemia. Provocative and suppressive testing may be used for the 
minority of patients with equivocal findings, although their role in the diagnosis of 
pheochromocytoma has diminished sharply (BONZANI et al. 1999). 
 Following the biochemical confirmation of pheochromocytoma, radiologic 
localization of the tumor is necessary to plan definitive surgical therapy. Not only does 
imaging delineate location, but it also aids in defining singularity, bilaterality, and 
possible multicentricity. Unsuspected metastatic lesions in bone, liver, or the lymph 
nodes may also be visualized. The three major modalities currently in use are computed 
tomography (CT) scans, magnetic resonance imaging (MRI), and 131-I-
metaiodobenzlguanidine-labeled nuclear scanning (MIBG). Additionally, imaging with 
positron emission tomography scans using isotope-labeled glucose or ephedrine, and 
scintiscans, with indium-labeled octreotide, are being evaluated in a number of endocrine 
centers. A CT scan is the most commonly used imaging test for pheochromocytoma. A 
CT scan can identify approximately 95% of all pheochromocytomas  it has the capacity 
to detect 1-cm tumors within the adrenal gland and 2-cm extraadrenal lesions. Several 
disadvantages to the CT scan have prompted some centers to adopt MRI as their first 
imaging modality. The CT scan entails radiation exposure, and it does require 
intravenous contrast material, with its risk of inducing a paroxysm (BONZANI et al. 1999). 
Not only does MRI define the anatomy but, on T2-weighted images, pheochromocytomas 
and paragangliomas show a characteristic and nearly unique high-intensity signal. Other 
advantages that may cause MRI to challenge CT scanning as the optimal localization test 
include its lack of radiation exposure, the clear definition of surrounding vascular 
structures, and the lack of interference from pre-existing metal clips. MIBG scan uses an 
agent that concentrates in the adrenergic vesicles. It has a sensitivity of 80% to 90%. 
Some centers have used MIBG as the primary modality to identify pheochromocytomas 
and rule out synchronous lesions or metastatic disease. Unfortunately, the iodine isotope 
is not readily available because of its short half-life and expense. The advantage of MIBG 
localization is offset by its limited availability and the cumbersome protocol for its use. 
The thyroid must be blocked with iodine before and after administration of the 
radioactive iodine (ROMAN et al. 2001).  
 
Pathology 
Pheochromocytomas are of variable size, ranging from 1 cm to several kilograms, 
but are normally between 50 and 200 g. In sporadic pheochromocytomas, even though 
lobulated, the tumor is actually a single neoplasm. In MEN 2, even though synchronous 
bilateral pheochromocytomas may not be present, the adrenal medulla of the contralateral 
adrenal will be hyperplasic and is thought to represent pretumor change analogous to C-
cell hyperplasia and medullary thyroid carcinoma. Fed by a rich blood supply, 
pheochromocytomas often have a purplish-gray hue when resected and frequently show 
demarcated areas of cystic necrosis. As stated previously, nearly 90% of 
pheochromocytomas are located within the adrenal glands. The remaining 10 to 15% are 
found from the neck to the bladder, typically along the course of the sympathetic chain 
(GRANT et al. 1997). 
Pheochromocytomas arise from chromaffin cells, which are of neuroectodermal 
origin. At about the fourth week of gestation, this neuroectodermal tissue separates away 
from the adjacent, newly formed neural tube. It eventually becomes positioned between 
this neural tube and the true ectoderm. This tissue is then neural crest, and cells from this 
crest begin migrating throughout the developing embryo, ultimately differentiating into 
the peripheral sympathetic nervous system, paraganglionic system, and adrenal medulla. 
These embryologic relationships help one better understand the coexistence of other 
diseases, such as the von Hippel-Lindae disease, with pheochromocytoma; affected 
tissues in these disorders are derived from adjacent neuroectodermal areas. Synthesis of 
norepinephrine begins in the cytoplasm of the cells. This metabolic pathway continues 
until the compound dopamine forms and is then taken up by intracellular granules and 
converted to norepinephrine by the enzyme dopamine beta-hydroxylase. Granular 
concentration of norepinephrine establishes equilibrium with free norepinephrine that 
freely diffuses into the cytoplasm of the cell; free norepinephrine can be converted into 
epinephrine via the action of phenyl ethanolamine n-methyl transferase. This newly 
formed epinephrine can be readily stored in separate intracellular granules within the cell 
(BONZANI et al. 1999). 
Microscopically, tumor cells closely resemble normal adrenal medulla. They are 
arranged in alveolus-shaped clusters, separated by endothelium-lined spaces. Numerous 
vessels are present, reflecting the abundant vascularity of these tumors. Tumor cell 
cytoplasm may be granular, basophilic, or eosinophilic. Nuclei are round or oval, with 
prominent nucleoli. Mitotic figures are scarce. Nuclear gigantisms and hyperchromatasia 
are seen but are not indicators of malignancy. As a rule, histologic appearance alone 
cannot distinguish between benign and malignant tumors (SCHLUMBERGER et al. 1992). 
Currently, the only definitive criterion for malignancy is the spread of the tumor to 
distant sites: lymph nodes, bone, lung, liver, brain, and the central nervous system are the 
most common sites. Because histologic examination cannot diagnose malignancy, some 
investigators have tried to identify any prognostic factors that may imply a malignant 
course. Tumor size and local tumor extension at the time of surgical exploration have 
been suggested, as has DNA ploidy. In a study of 184 pheochromocytoma patients by 
Nativ and colleagues, 84% of those with vascular endothelial invasion and 100% of 
patients with regional or distant metastases had either aneuploid or tetraploid DNA 
content. All 12 patients dying of their disease had abnormal DNA ploidy, whereas no 
patient with diploid DNA died (NATIV et al. 1992).  
 
Treatment 
 Once the diagnosis of pheochromocytoma is firmly established, the patient must 
be prepared for surgical resection. Optimization of the patient requires adequate blood 
pressure control and correction of intravascular fluid deficits. Sometimes this is not 
feasible; conditions mandating emergent surgical removal include malignant 
hypertension, acute cardiovascular complications (sporadic ventricular arrhythmias, 
impending heart failure), and abdominal morbidity (tumor hemorrhage). In most cases, 
however, preoperative management can be instituted. The mainstay of preoperative 
treatment is alpha-adrenergic blockade. Instituted 1 to 3 weeks before surgery, this 
normalizes blood pressure, controls paroxysms, and allows for intravascular volume 
expansion. Phenoxybenzamine (Dibenzyline) is the drug of choice because of its 
irreversible binding and its 100-fold greater potency at the alpha-1, rather that the alpha-
2, receptor. Phentolamine (Regitine) is a competitive norepinephrine antagonist that also 
may be used preoperatively. This agent is less effective than phenoxybenzamine, as its 
effects are transient (requiring more frequent dosing intervals). Side effects are prominent 
and include nausea, vomiting, nasal congestion, and ejaculatory dysfunction, all to a 
greater degree than that of the other alpha-blockers. For these reasons, phentolamine is 
essentially reserved for intraoperative hypertensive crises. Other pharmacologic 
management will center around beta-adrenergic blockade. Treatment with beta-blockade 
is indicated for the appearance of tachycardia (greater than 140 beats per minute) and 
arrhythmias while on alpha-blocker therapy, as well as for purely epinephrine-secreting 
tumors. The standard agent is propranolol, a competitive beta-receptor blocker. Beta-
blockade is to be instituted only after alpha-blockade has been achieved. Unopposed 
beta-blockade can cause worsening hypertension by blocking the vasodilatory effects of 
epinephrine, resulting in enhanced pressor response to norepinephrine. More 
cardioselective beta-blockers such as metoprolol and atenolol may decrease the risk. 
Beta-blockers must be used with caution in elderly patients and those with proven or 
suspected heart disease, because it may promote profound bradycardia, myocardial 
depression, and congestive heart failure. When used, they have been commonly instituted 
3 to 7 days before surgery (BONZANI et al. 1999). 
 
Surgery 
 The treatment of pheochromocytoma is surgical extirpation. Close intraoperative 
monitoring with central venous and arterial pressure monitoring, an experienced 
anesthesiologist, and careful use of anesthetics with minimal myocardial depressant 
effects are important for safe surgery. The use of hemocynamic stabilizing drugs such as 
nitroprusside, phentolamine, and esmolol are commonly required at different stages of 
the procedure. Regardless of the location of the pheochromocytoma, the most critical part 
of the surgery is the ligation of the adrenal vein. The patient may become hypotensive 
because of the short half-life of catecholamines. The anesthesiologist needs to be warned 
when this point of the surgery has been reached. A variety of incisions and approaches 
have been used for either unilateral adrenal resection or bilateral excision with wide 
retroperitoneal lymphadenectomy or extraadrenal tumor resections. The open anterior 
approach allows access to both adrenal glands and the intraabdominal and retroperitoneal 
areas. The open approach enables the resection of other organs as necessary in genetic 
syndromes such as VHL or NF1. The open lateral or retroperitoneal approach may use 
30- to 45-degree lateral decubitus positioning of the patient and subcostal/flank incision, 
and the open posterior approach has patients in the prone position, and a J or hockey 
stick incision is made curving along the 12th rib, which is then resected for better 
exposure. This approach is more difficult for larger tumors and involves more 
manipulation of the tumor than the anterior approach. The open thoracoabdominal 
approach is seldom employed and is most often used with very large, malignant tumors 
when en bloc resection is necessary. The patient is positioned in a slight lateral angle, and 
the abdominal cavity is not necessarily entered, unless needed (ROMAN et al. 2001). 
 Since the early 1990s, laparoscopic adrenalectomy has become the procedure of 
choice for tumors without overt signs of malignancy, such as locoregional invasion, 
adenopathy, or metastases. It is clearly superior to the open approaches by reducing 
postoperative hospital stays, return to normal physical activity, and wound complications. 
The most commonly employed approach is the transabdominal lateral approach. The 
patient is placed in flexed 90-degree decubitus position, allowing gravity to help in organ 
dissection. For bilateral adrenalectomy, the patient may be turned from side to side for 
respective adrenal gland resection with excellent results. In patients with MEN 2 
syndrome who present with bilateral adrenal pheochromocytomas, a bilateral 
laparoscopic total adrenalectomy will be curative in most patients, yet it will render the 
patients anadrenal. The laparoscopic retroperitoneal approach may be used if the patient 
has significant intraabdominal adhesions from prior surgery, which may preclude a 
laparoscopic transabdominal approach. It is difficult for tumors larger than 4 to 5 cm 
(ROMAN et al. 2001). 
 
Post-op 
 Most patients will have an uneventful postoperative course, yet rebound 
hypotension may occur in some patients if phenoxybenzamine is used, given its long 
half-life. Fluid and occasional vasopressor support is necessary. In patients who may 
have developed catecholamine excess cardiomyopathy, treatment of postoperative 
hypotension with fluid resuscitation can be hazardous. This complication can be avoided 
if adequate alpha 1-specific blockade is achieved preoperatively. Approximately half of 
all patients will remain hypertensive long term. This may be because of chronic vascular 
or metabolic changes from prolonged exposure to catecholamines, or to preexisting 
essential hypertension. Because pheochromocytomas may recur or have metastatic 
development many years after extirpation of the primary tumor, patients should have 
lifelong follow-up with yearly or biannual biochemical screening. Imaging studies are 
warranted only if there is evidence of catecholamine excess. The lifetime rate of 
recurrence or metastatic development is 6.5% to 15%. Surgical extirpation is curative in 
up to 85% to 90% of patients. The development of laparoscopic surgical approaches has 
had a significant impact on the recovery and wound complications of surgery (ROMAN et 
al. 2001). 
 
Introduction 
 Pheochromocytoma is a rare neuroendocrine tumor histologically characterized 
by chromaffin tissue and is comprised of catecholamine-containing neurosecretory 
granules. Pheochromocytomas are primarily located in the adrenal medulla, but may also 
arise in the dorsal root ganglia of the sympathetic nervous system. Pheochromocytomas 
cause endocrine hypertension by oversecretion of catecholamines. Such hypertension can 
be sustained, or paroxysmal, and may lead to death from cardiovascular or 
cerebrovascular disease (KOCH et al. 2001). Although pheochromocytomas are known to 
be associated with several hereditary syndromes, relatively little is known about other 
genetic abnormalities involved in their tumorigenesis. 
Abrogation of the Rb/p16 tumor-suppressive pathway is thought to be an 
important mechanism in the development of many human cancers (KAMB et al. 1994; 
SERRANO et al. 1993; NOBORI et al. 1994). This pathway is a well described component of 
global cell cycle regulation and inactivation may occur through alterations of Rb, CDK4, 
cyclin D, or p16. These alterations occur almost universally exclusively of each other, 
indicating that only one event is necessary for abrogation of the pathway. The p16 gene 
product is a 16 Kd protein that inhibits formation of cyclin D/CDK4 complexes. 
Consequent phosphorylation of the Rb protein results in the release of activated 
transcription factors and progression of the cell cycle through the G1/S checkpoint. 
Inactivating p16 gene alterations occur frequently in a number of human cancer cell lines 
and primary tumors (NOBORI et al. 1994). Mechanisms of inactivation include 
homozygous deletion, mutation, and aberrant methylation of 5' CpG islands (HERMAN et 
al. 1995; MERLO et al. 1995; GONZALEZ-ZULUETA et al. 1995). Research previously 
performed in the laboratory demonstrates that inactivating alterations of p16 occur 
frequently in chemically induced hamster pancreatic tumors (LI et al. 2004) and human 
pancreatic endocrine tumors (MUSCARELLA et al. 1998). Pheochromocytomas are a rare 
endocrine tumor and data regarding the role of p16 inactivation in these tumors is 
currently limited. The purpose of this study was to determine the frequency of p16 
inactivation in pheochromocytoma specimens obtained at the time of surgical resection at 
The Ohio State University Medical Center.   
All tissue specimens were obtained from patients undergoing surgical resection of 
pheochromocytomas, and foci of tumor cells were identified by a pathologist under light 
microscopy after staining with hematoxylin and eosin. To test the described mechanisms 
of inactivation, the genetic status of p16 gene in pheochromocytoma specimens was 
analyzed.  The techniques of multiplex real-time PCR, direct DNA sequencing, and 
methylation-specific PCR were used to evaluate tumor specimens for homozygous 
deletions, point mutations, and abberant methylation of 5 CpG islands, respectively. In 
order to determine whether potentially inactivating alterations were associated with loss 
of p16 expression, immunohistochemical analysis of tissue sections was performed using 
p16 monoclonal antibodies. 
 
Materials and methods 
Tumor specimens and genomic DNA extraction 
 Seventeen pheochromocytoma tumors from 15 patients (there were two patients 
with bilateral tumors) were obtained at the time of surgical resection at The Ohio State 
University Medical Center. Following resection, the tissues were fixed in formalin and 
paraffin-embedded according to routine protocol. The diagnosis of pheochromocytoma 
was made preoperatively based on clinical presentation, urine biochemical analysis, and 
radiologic imaging for tumor localization. Histological analysis confirmation of the 
tumor type was made by staff pathologists after hematoxylin and eosin staining. The 
study was approved by the Institutional Review Board. 
 A ChargeSwitch gDNA mini tissue extraction kit was used for genomic DNA 
extraction. Two cores of tumor (10 mg) were separated from archived paraffin blocks and 
confirmed by the pathologist (WLF). These were digested with lysis buffer (L13) and 
proteinase K at 65ûC overnight. RNaseA was added to each of the microcentrifuge tubes 
containing these tissue samples after cooling. This liquid was transferred to a fresh tube 
and centrifuged at maximum rpm. Supernatants were placed into fresh tubes and treated 
with purification buffer (N5) by tip-mixing. Magnetic beads were added and evenly 
suspended for a short incubation period at room temperature. The target DNA was bound 
to these beads at this point. The beads were separated on the ChargeSwitch MagnaRack, 
allowing the remaining supernatant to be removed with pipettes and discarded. The beads 
were fully redispersed in wash buffer (W12), and then separated on the MagnaRack two 
additional times. Resuspension in elution buffer (E5) by tip-mixing was performed in 
order to separate magnetic beads from the target DNA. Overnight incubation in a 55ûC 
water bath was performed in order to improve the efficiency of this detachment. The 
microcentrifuge tubes were separated on the MagnaRack and the solution containing 
purified genomic DNA was transferred into fresh tubes and stored at -20ûC until needed 
for further analyses. The amount of DNA yielded from purification was determined by 
spectrophotometry. 
 
Real-time PCR to detect homozygous deletions in human p16 exon 2 
Amplification reactions were carried out using the Cepheid Smart Cycler.  
Forward (5-GGCTCTACACAAGCTTCCTTTCC-3) and reverse (5-
TCATGACCTGCCAGAGAGAACA-3) primers (Life Technologies) were used at a 
final concentration of 0.2 µM. The dual-labeled fluorogenic probe (5-FAM-
CCCCCACCCTGGCTCTGACCA-TAMRA-3) was used at the final concentration of 
0.1 µM (CARTER et al. 2001).  Each reaction was performed in the presence of 200 uM 
dNTPs, 3 mM MgSO4, 1.25 units of Taq polymerase (Stratagene), 1X Additive (1 mg/ml 
BSA, 750 mM Trehalose and 1 % Tween 20), and 2.0 µl of genomic DNA (containing 
about 5 to 30 ng DNA).  The sample was subjected to 96°C for 1 min, followed by 55 
cycles of 30 s at 95°C, 30 s at 62°C, 45 s at 68°C.  A final extension step was performed 
at 68°C for 5 min.  A housekeeping gene, β-actin was co-amplified as an internal control.  
The primers and fluorogenic probe for the internal controls are: forward primer, 5-
AGCGCGGCTACAGCTTCA-3; reverse primer, 5-
CGTAGCACAGCTTCTCCTTAATGC-3; and the probe, 5-TET- 
ATTTCCCGCTCGGCCGTGGT-TAMRA-3.  All experiments were performed in 
duplicate. 
 
p16 gene deletion analysis  
The accuracy of the above real-time PCR assay was verified using a series of 
mixtures of genomic DNA from human Hela cells (+/+) and Mia PaCa-2 cells (-/-) at 
various ratios (Hela:Mia PaCa-2 = 100:0, 75:25, 50:50, 25: 75, 0:100).  Multiplex real-
time PCR was performed and the resulting cycle threshold (Ct) values were normalized 
against those of Hela using the following equation: 
                                          ∆∆Ct = ∆Ctp16 - ∆Ct β-actin,  
where ∆Ctp16 is equal to Ctp16 of a sample minus Ctp16 of Hela, and ∆Ct β-actin is the net Ct 
β-actin of a sample deducted by Ct β-actin of Hela (LI et al. 2004).  While ∆Ct β-actin is 
correlated with the difference in total genomic DNA concentrations between the sample 
and Hela, ∆Ctp16 is ascribed to the total difference in p16 gene concentrations between 
the sample and Hela (wild type), including the difference in total genomic DNA 
concentrations and the difference in the p16 gene dosage.  Therefore, ∆∆Ct reflects the 
difference in the p16 gene dosage.  When the ∆∆Ct values were plotted against the 
relative ratio of normal p16 DNA in the mixtures (in exponential form), a linear graph 
with a correlation coefficient of 0.992 was obtained, indicating that the relative 
concentration of p16 gene can be accurately measured using this technique (POI et al. 
2001).  On the basis of this observation, the p16 gene dosage in 17 pheochromocytoma 
tumor specimens was determined using the above real-time PCR assay, and the results 
were interpreted as follows (CARTER et al. 2001): relative concentration <25%, p16 
homozygous deletion (-/-); relative concentration >25% and <75%, p16 hemizygous 
deletion (+/-); and relative concentration >75%, p16 wild type (+/+).   
 
Methylation-specific PCR of a CpG island inhuman p16 promoter 
Genomic DNAs from tumor tissues were bisulfate-modified using the CpGenome 
DNA modification kit (Cat. # S7820, Serologicals, GA), and methylation at the promoter 
region of p16 was analyzed using a CpG WIZ p16 Amplication Kit (Cat. # S7800, 
Serologicals, GA).  The PCR mixture contained 1 X PCR buffer, 1 X enhancer, 1.5 mM 
MgCl2, dNTPs (each at 1.25 mM), 1 unit of Platinum Taq DNA polymerase 
(Invitrogene), primers (0.2 µM each) and 10 µl of bisulfide-modified DNA in a final 
volume of 50 µl.  Amplification was performed in a GeneAmp 9700 Thermal Cycler (PE 
Applied Biosystems) with PCR conditions of 95°C for 2 min followed by 40 cycles of 
95°C for 45 s, 60°C for 45 s, 72°C for 60 s, and a final elongation step of 72°C for 5 min.  
Of note, the primer sequences in this kit are not disclosed due to proprietary reasons.  The 
PCR products were analyzed by electrophoresis on a 10% PAGE gel.  Fragments 
amplified from methylated and unmethylated p16 gene were 145 and 154 bp, 
respectively, and both negative and positive controls were provided by the manufacturer. 
 
Automatic sequencing of p16 exons 1 and 2 
Human p16 exon 1 was amplified by PCR using the following intron-based 
primers: for exon 1, 5-GCT GCG GAG AGG GGG AGA GCA GGC A-3 (forward) 
and 5-GCG CTA CCT GAT TCC AAT TC -3 (reverse) (POI et al. 2001).  Exon 2 was 
amplified in two fragments (2a and 2b) with at least one of the primers in a set located 
within an intron to exclude coamplification of a similar gene family member or potential 
pseudogenes.  The primers for 2a are 5-ACA AGC TTC CTT TCC GTC ATG CCG-3 
(forward) and 5-CCA GGC ATC GCG CAC GTC CA-3 (reverse), while the 2b primers 
are 5-TTC CTG GAC ACG CTG GTG GT-3 (forward) and 5-TCT GAG CTT TGG 
AAG CTC TCA G-3 (reverse).  Potential mutations at exon 3 were not analyzed due to 
the following fact that exon 3 represents only 3% (12 bp) of p16 gene and mutations at 
this region do not cause significant changes in the structure and function of P16 protein.  
The PCR mixture contained 1 X PCR buffer, 1.5 mM MgCl2, dNTPs (each at 1.25 mM), 
1.0 µM of each primer, 1 unit of Taq DNA polymerase (Invitrogene), 1.5 X enhancer, 
and 4 µl of genomic DNA in a final volume of 50 µl.  The whole procedure included: 
96°C for 2 min (1 cycle); 30 s at 95°C, 30 s at 56°C, and 30 s at 72°C (50 cycles); 5 min 
at 72°C (1 cycle).  The PCR products were purified using a PCR Product Purification kit 
(Qiagen), and subsequently sequenced using an ABI 377A automated DNA sequencer.  
Both strands of the PCR-amplified fragments were sequenced to confirm the mutations. 
 
Tissue Microarray (TMA) 
 The methods for TMA creation have been described previously (Arch Pathol Lab 
Med 2005, 129: 1100-5). Briefly, formalin-fixed, paraffin-embedded tissues were 
obtained from the archival files at the Ohio State University Department of Pathology. 
Two tissue cores (1.5 mm diameter each) were punched out of each donor paraffin block 
and transferred to each of the recipient TMA blocks using a precision instrument 
(Beecher Instruments, Silver Spring, MD).  Paraffin embedded tissue was cut at 4 
microns and placed on positively charged slides then heated to 40°C for 30 minutes. 
After leveling paraffin and cores, the array was cooled to 4°C for 15 minutes. Cores were 
also obtained from adjacent normal adrenal tissue. 
 
Immunohistochemistry (IHC) for p16 
 TMA slides were placed in a 60 °C oven for 1 hour, cooled, and deparaffinized 
and rehydrated through xylenes and graded ethanol solutions to water. All slides were 
quenched for 5 minutes in a 3% hydrogen peroxide solution in water to block for 
endogenous peroxidase. Antigen retrieval was performed by a heat method in which the 
specimens were placed in a citric acid solution (Target Retrieval Solution, pH 6.1, 
DakoCytomation, Carpinteria, CA) for 25 minutes at 94°C using a vegetable steamer and 
cooled for 15 minutes in solution.  Slides were placed on a DakoCytomation Autostainer  
immunostaining system for use with immunohistochemistry. The primary antibody was 
added using Cell Marque's (Hot Springs, Ark) monoclonal anti-p16 (clone 16PO4) at a 
dilution of 1:20 and incubated for 60 minutes. A labeled streptavidin-biotin complex was 
used for detection and visualization occurred after the application of a 3,3-diamino-
benzidine chromogen.  Slides were then counterstained in Richard Allen hematoxylin, 
dehydrated through graded ethanol solutions and cover-slipped. Positive and negative 
controls stained appropriately. All TMA slides were read by a senior pathologist (WLF). 
The percentage of cells with convincing nuclear p16 staining was determined for each 
sample. 
 
Results 
Seventeen tumor samples obtained from fifteen patients were analyzed for p16 
genetic alterations and altered expression by the techniques described above. The genetic 
data are summarized in Table 1. Real-time PCR-based deletion analysis indicated that 
two specimens harbored hemizygous deletions (+/-) and two specimens harbored 
homozygous deletions (-/-) for a total frequency of 23.5%. There were no p16 mutations 
identified by direct sequencing. Methylation-specific PCR analysis indicated 5 CpG 
island methylation in 47.1% of specimens. Overall, 64.7% of specimens demonstrated 
evidence of potentially inactivating p16 deletions or methylation. One tumor (specimen 
#1) demonstrated both methylation and hemizygous deletion, suggesting that the 
undeleted allele was suppressed by methylation. Genomic DNA extracted from 
histologically normal appearing adjacent adrenal tissue was assessed for each specimen, 
and no potentially inactivating p16 abnormalities were identified. 
 
Table 1. Genetic analysis of p16 alterations in pheochromocytoma specimens. 
 
Patient/Specimen Deletion 
Analysis 
Methylation 
Status 
Mutation 
Analysis 
Inactivation 
1 +/- + - + 
2 -/- - - + 
3 +/+ - - - 
4R +/+ + - + 
4L +/+ - - - 
5 +/+ - - - 
6 +/+ + - + 
7 +/+ + - + 
8 +/- - - + 
9 +/+ - - - 
10 +/+ - - - 
11R +/+ - - - 
11L +/+ + - + 
12 +/+ + - + 
13 -/- - - + 
14 +/+ + - + 
15 +/+ + - + 
 
  The IHC data were difficult to interpret because of lack of sufficient cells or 
tissue in 52.9% of specimens. In general, lack of nuclear p16 IHC staining corresponded 
with the data from the DNA analysis (Figure 1).  Two specimens lacking identifiable 
inactivating events demonstrated loss of p16 expression (>50% decrease in nuclear 
staining) when compared to matched-normal tissues. It is possible that p16 expression 
may have been inactivated by alternative mechanisms in these patients. When this is 
considered, decreased p16 expression and/or potentially inactivating events occurred in 
76.5% of the specimens analyzed.  Patient #11 was one of two patients noted to have 
bilateral pheochromcytomas. The left-sided tumor was positive for p16 methylation while 
the right-sided tumor demonstrated no potentially inactivating alterations. In this 
instance, the genetic data correlated nicely with the IHC data (5% vs. 25% nuclear 
staining). No p16 abnormalities were identified in either tumor in the only other patient 
with bilateral tumors (patient #4), and both tumors demonstrated relatively high nuclear 
expression of p16 by IHC. All tumors demonstrating relatively high expression of p16 
(>25%) did not contain potentially inactivating p16 alterations. 
 
Discussion 
 Like many endocrine tumors, pheochromocytoma is rarely seen but commonly 
discussed. Hereditary syndromes have been known to be associated with 
pheochromocytomas for many years and the molecular basis for these syndromes is 
currently under investigation (LENDERS et al. 2005). There are currently four hereditary 
syndromes associated with pheochromocytoma development, including multiple  
  
 
 
 
 
 
Figure 1. Pheochromocytoma immunohistochemical data. A) H&E stain; B) p16 
negative. Note that there is some staining in the endothelial cells; C) p16 focally 
positive. (All images are 40x magnification). 
 
endocrine neoplasia type 2 (MEN 2), von Hippel-Lindau (VHL) disease, 
neurofibromatosis type 1 (NF 1), and hereditary paraganglioma and SDHD gene-related 
tumors (KOCH et al. 2001). As yet unidentified genes are also felt to be responsible for an 
additional number of familial cases. In the past it has been accepted that 10% of 
pheochromocytomas are familial, but recent data indicate that up to 12-33% of patients 
with presumably sporadic pheochromcytomas harbor germline mutations of VHL, RET, 
SDHD, or SDHB (NEUMANN et al. 2002, GIMENEZ-ROQUEPLO et al. 2003, AMAR et al. 2004). 
These findings have resulted in the establishment of less stringent criteria for genetic 
screening of affected individuals in the hope that surveillance will result in earlier 
detection of recurrent or associated tumors in patients and earlier detection of tumors in 
relatives. 
 Despite the advances that have been made in clinical cancer genetics for patients 
with familial pheochromocytomas, relatively little is known about the genetic changes 
that occur during the pathogenesis of sporadic pheochromcytomas. Surprisingly, RET, 
VHL, SDHB, and ADHD mutations do not appear to play a significant role in the 
development of sporadic pheochromocytomas (MAHER et al. 2002). Furthermore, there is 
also a paucity of data regarding secondary molecular events contributing to 
pheochromocytoma tumorigenesis. Mutations in c-mos, p53, endothelin B, RASSF1A, ras 
and MEN1 have not been identified in series of screened tumors (DANNENBERG et al. 
2003). Although increased expression of c-myc mRNA has been identified in malignant 
A B C
pheochromocytomas, no amplifications or rearrangements of the encoding genes have 
been seen (GOTO et al. 1990). 
 Abrogation of the Rb/p16 tumor-suppressive pathway is thought to be an 
important mechanism in the development of many human cancers (KAMB et al. 1994, 
SERRANO et al. 1993, NOBORI et al. 1994). This pathway is a well-described component of 
global cell cycle regulation and inactivation may occur through alterations of Rb, CDK4, 
cyclin D, or p16. These alterations occur almost universally exclusively of each other, 
indicating that only one event is necessary for abrogation of the pathway. The p16 gene 
product is a 16 Kd protein that inhibits formation of cyclin D/CDK4 complexes. 
Consequent phosphorylation of the Rb protein results in the release of activated 
transcription factors and progression of the cell cycle through the G1/S checkpoint 
(Figure 2). Inactivating p16 gene alterations occur frequently in a number of human 
cancer cell lines and primary tumors (NOBORI et al. 1994). Mechanisms of inactivation 
include homozygous deletion, mutation, and aberrant methylation of 5 CpG islands 
(HERMAN et al. 1995; MERLO et al. 1995; GONZALEZ-ZULUETA et al. 1995). As stated 
previously, current data regarding alterations of Rb/p16 tumor-suppressive pathway in 
pheochromocytomas are limited, although loss of Rb expression, as determined by IHC, 
has been identified in 40-70% of adrenal pheochromocytomas (LAM et al. 2001; GUPTA et 
al. 2000). 
 We report here the first evidence of p16 homozygous and hemizygous deletions in 
human pheochromocytoma specimens. Aguiar had previously used a semi-quantitative, 
standard multiplex PCR assay and found no homozygous deletions in 26 analyzed 
specimens (AGUIAR et al. 1996). In that study, tumors were not evaluated for mutations or 
hypermethylation, and the findings were not confirmed by IHC. Although an 
appropriately designed gene dosing curve was used as a control and appeared to confirm 
the validity of the findings, we believe that the real-time based multiplex PCR performed 
in the current study is more sensitive. In a more recent study of 25 pheochromocytoma 
tumor specimens, p16 hypermethylation was identified in 24% of tumor specimens 
(DAMMAN et al. 2005). Hypermethylation was noted to be particularly associated with 
hereditary pheochromocytomas, as 42% of familial tumors exhibited p16 
hypermethylation compared to only 8% of sporadic tumors. These findings are consistent  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The p16/Rb pathway. 
 
with our data, which show p16 hypermethylation in 47.1% of specimens. Mutant mouse 
studies of p16 +/- PTEN +/-,  p16 -/- PTEN +/- , and p16 +/+ PTEN +/- mice indicate that 
there is functional synergy between p16 and PTEN that is manifested most predominantly 
by an increased predisposition towards pheochromocytoma development in mice 
harboring hemizygous, and particularly homozygous, p16 deletions (YOU et al. 2002). 
These data further support a role for Rb/p16 pathway alterations in pheochromocytoma 
tumorigenesis. 
 In conclusion, we report here that p16 alterations, by deletion (23.5%) and 
methylation (47.1%), occur commonly in human pheochromcytoma specimens with an 
overall total of 64.7% of specimens exhibiting some type of genetic abnormality. The 
data are generally supported by the IHC findings, which indicate that decreased 
expression of p16 might occur in up to 76.5% of specimens. These findings support 
further evaluation of Rb/p16 pathway abnormalities in pheochromocytomas and 
contribute to our current understanding of pheochromocytoma pathogenesis. 
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